Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Casey Woodring
JPMorgan Chase & Co, Research Division

All right. Great. Welcome, everybody. I’m Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan. Welcome to our conference. Pleased to be joined by Tempus AI, CEO, Eric Lefkofsky. We’ll go through the corporate presentation, then leave time for the Q&A afterwards. Eric, all yours.

Eric Lefkofsky
Co-Founder, CEO, President & Chairman

Thank you. Welcome. There’s seats up here — for people in the back, but by all means, feel free to walk up. So I’ll try to give you a little context of what we’ve been building at Tempus and a little bit about where we’re at now.

So 10 years ago, we started Tempus to solve a single problem, could AI-enabled diagnostics unlock precision medicine. Essentially, could we use diagnostics as a vehicle to make precision medicine as opposed to targeted medicine a reality. In order to do so, you really need two things. You need access to vast amounts of proprietary data to train models and uncover insights and you need a distribution system to deliver those insights to the hands of physicians and patients. Most people have failed historically at having one or both of those.

We have spent the last 10 years building both. We’ve built up a dataset that is now quite substantial. And equally importantly, we built up distribution capabilities to take those insights and distribute them to tens of thousands of physicians across the country, reaching millions of patients to advance therapy selection, what therapeutic path should my patient be on; to advance clinical trial matching, is